Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyMichèle Cavo, Michele Baccarani, Patrizia Tosi et al.|Journal of Clinical Oncology|2007Cited by 374
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, Alessandro Rambaldi et al.|The Lancet Haematology|2020Cited by 58
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.Michèle Cavo, Michele Baccarani, Paola Tacchetti et al.|Blood|2009Cited by 48
Thalidomide–dexamethasone as up‐front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low‐dose warfarinMichela Cini, Michèle Cavo, Elena Zamagni et al.|European Journal Of Haematology|2010Cited by 34
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantationCarolina Terragna, Michèle Cavo, Matteo Renzulli et al.|Annals of Hematology|2013Cited by 10